Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A031701||Alliance||A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations||Adult CIRB - Late Phase Emphasis||Available to Open|
|A211701||Alliance||A Prospective Study to Establish a New Onset Diabetes (NOD) Cohort||Cancer Prevention and Control CIRB||Available to Open|
|A151804||Alliance||Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091304||Alliance||A Phase I /Randomized Phase II Study of MLN0128 vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|A031102||Alliance||A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel; Ifosfamide; and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA9161||Alliance||A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011202||Alliance||A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221504||Alliance||A Randomized; Double-Blind; Placebo-Controlled Pilot Study of an Oral; Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)||Cancer Prevention and Control CIRB||Available to Open|
|A041501||Alliance||A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031801||Alliance||A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RADICAL)||Adult CIRB - Late Phase Emphasis||Available to Open|